Embedded Sensing Technology Aids Cardiac Ablation

The EPi-Sense CA device for radiofrequency (RF) endoscopic coagulation of cardiac tissue uses sensing technology to allow electrophysiologists (EPs) to follow epicardial device positioning and lesion creation in real time, utilizing navigational mapping technology. Additionally, by using the sensors during the epicardial ablation procedure, the ablated tissue’s electrical impulses can be measured to predict lesion completeness before repositioning the device. From a safety perspective, the sensors use electrical feedback to ensure the device is properly positioned on the cardiac tissue, and that the CA energy is directed into the heart.

The EPi-Sense device integrates suction, perfusion, and RF energy specifically designed for the minimally invasive application. A surgical maze pattern is used maintain constant contact with the cardiac tissue in order to deliver consistent RF energy over the lesion. Proprietary suction capabilities also help to ensure consistent and predictable contact with cardiac tissue during the creation of linear lesions. The EPi-Sense CA device is a product of nContact (Morrisville, NC, USA), and has been approved by the US Food and Drug Administration (FDA).

“The EPi-Sense is another step forward in advancing epicardial ablation techniques to address limitations of other ablation devices, potentially creating a better experience for physicians, and ultimately, patients,” said John Funkhouser, president of nContact.

Catheter ablation is an invasive procedure used to remove a faulty electrical pathway from the hearts of those who are prone to developing cardiac arrhythmias such as atrial fibrillation (AF), atrial flutter, supraventricular tachycardias (SVT), and Wolff-Parkinson-White syndrome.

Related Links:
nContact